Fig. 1: A higher expression level of MTA2 predicts a poorer prognosis of pancreatic cancer.
From: MTA2-mediated inhibition of PTEN leads to pancreatic ductal adenocarcinoma carcinogenicity
a The relative expression of MTA2 was measured in different pancreatic ductal adenocarcinoma (PDAC) cohorts in GSE28735, PACA-AU ICGC, and TCGA databases. b The Kaplan–Meier analysis was performed using the GSE28735, PACA-AU ICGC, and TCGA databases, and showed that a higher expression level of MTA2 predicted a poorer overall survival. c Tissue microarray (TMA) was used to perform immunohistochemical staining. Representative sections of normal and PDAC tissues stained with anti-MTA2 antibody as well as quantitative immunohistochemistry results of MTA2 expression was presented. d The expression of MTA2 was acquired in PDAC specimens and the adjacent normal pancreatic tissues. Images were taken from the online database of the Human Protein Atlas. e qRT-PCR and western blot analyses were used to measure the expression of MTA2 in the human pancreatic cancer cell lines MIA Paca-2 and PANC-1 cells, and the human pancreatic duct epithelial cell line HPDE6c7 was included as control. Values are mean ± S.D. n = 3. *P < 0.05
